Fuchs Endothelial Corneal Dystrophy- Pipeline Insight, 2024

Fuchs Endothelial Corneal Dystrophy- Pipeline Insight, 2024

DelveInsight’s, “Fuchs Endothelial Corneal Dystrophy- Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Fuchs Endothelial Corneal Dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Fuchs Endothelial Corneal Dystrophy: Understanding

Fuchs Endothelial Corneal Dystrophy: Overview

Fuchs endothelial corneal dystrophy is the most common form of corneal dystrophy. It is an inherited condition caused by changes in various genes, which lead to the abnormal function of the innermost layer of the cornea, the endothelium. The endothelium is made up of a single layer of cells (endothelial cells) which rest on a thin membrane (Descemet’s membrane). Endothelial cells normally function to keep the cornea clear and transparent by pumping fluid out of the stroma (the thick middle layer of the cornea). A small number of endothelial cells are normally lost when a person gets older but in Fuchs dystrophy this process is accelerated, causing the cornea to swell and become cloudy (corneal oedema), which in turn makes vision blurry. Most patients do not experience any symptoms when the first sign of Fuchs dystrophy is detected (known as corneal guttata), often by an optician during a routine eye check. As the condition progresses slowly over time, a variety of symptoms can occur: Glare due to scattering of light by the corneal guttata, blurry vision which tends to be worse in the morning and improves throughout the day (due to fluid accumulation in the stroma overnight which dries up from the corneal surface once the eyes are open), progressive worsening of vision as corneal oedema becomes more permanent due to further loss of endothelial cells. So far changes in 5 genes have been identified to cause Fuchs dystrophy, and the most common gene responsible for Fuchs dystrophy is the TCF4 gene. About 75% of cases in the Caucasian population are caused by a specific mutation (CTG18.1 expansion) in the TCF4 gene. Mutations in the COL8A2 gene is specifically associated with a rare type of Fuchs dystrophy that occur in children. Fuchs dystrophy is usually diagnosed with an eye examination by an ophthalmologist. There are usually tiny lumps inside the cornea called guttata which is characteristic of this condition. Though the underlying genetic cause of Fuchs dystrophy cannot yet be treated, several treatment options are available to improve symptoms. These include: Glasses or rigid contact lenses to sharpen the vision, saline eye drops can help to reduce corneal swelling that leads to blurry vision in the mornings, a specialized contact lens (bandage contact lens) can be used to ease the pain caused by broken blisters on the corneal surface while waiting for corneal transplant, corneal transplant surgery is required if there is significant pain associated with the blisters or if the vision is severely affected and not amenable to eye drops.

""Fuchs Endothelial Corneal Dystrophy- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Fuchs Endothelial Corneal Dystrophy pipeline landscape is provided which includes the disease overview and Fuchs Endothelial Corneal Dystrophy treatment guidelines. The assessment part of the report embraces, in depth Fuchs Endothelial Corneal Dystrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Fuchs Endothelial Corneal Dystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Fuchs Endothelial Corneal Dystrophy R&D. The therapies under development are focused on novel approaches to treat/improve Fuchs Endothelial Corneal Dystrophy.

Fuchs Endothelial Corneal Dystrophy Emerging Drugs Chapters

This segment of the Fuchs Endothelial Corneal Dystrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Fuchs Endothelial Corneal Dystrophy Emerging Drugs

• TTHX 1114: Trefoil Therapeutics

TTHX1114 is a proprietary, engineered form of the naturally occurring molecule Fibroblast Growth Factor-1 (FGF-1), which naturally functions to stimulate cell proliferation and migration as well as protect cells from stress and injury. TTHX1114 has been engineered to increase FGF-1’s pharmacodynamic half-life, enabling its use as a pharmaceutical. TTHX1114 has been shown in preclinical studies to stimulate endothelial cell proliferation and migration, and drive regeneration of the corneal endothelial layer. In addition to the trial in patients undergoing DSO surgery, the company is conducting a Phase 1/2 trial (“INTREPID”) to evaluate TTHX1114’s safety and ability to stimulate the regeneration of corneal endothelial cells lost due to corneal endothelial disorders, including FECD.

• Ripasudil hydrocholoride hydrate: Kowa Pharmaceutical

Ripasudil hydrochloride hydrate is a rho-kinase inhibitor, it has been suggested that the compound may also act on other kinases in the eye, leading to investigations of its applicability to other ophthalmic diseases. As part of these efforts, development of the compound as a treatment for Fuchs endothelial corneal dystrophy (FECD) is underway.

Further product details are provided in the report……..

Fuchs Endothelial Corneal Dystrophy: Therapeutic Assessment

This segment of the report provides insights about the different Fuchs Endothelial Corneal Dystrophy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Fuchs Endothelial Corneal Dystrophy

There are approx. 5+ key companies which are developing the therapies for Fuchs Endothelial Corneal Dystrophy. The companies which have their Fuchs Endothelial Corneal Dystrophy drug candidates in the most advanced stage, i.e. phase II include, Trefoil Therapeutics.

• Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Fuchs Endothelial Corneal Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Fuchs Endothelial Corneal Dystrophy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Fuchs Endothelial Corneal Dystrophy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fuchs Endothelial Corneal Dystrophy drugs.

Fuchs Endothelial Corneal Dystrophy Report Insights

• Fuchs Endothelial Corneal Dystrophy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Fuchs Endothelial Corneal Dystrophy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Fuchs Endothelial Corneal Dystrophy drugs?
• How many Fuchs Endothelial Corneal Dystrophy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Fuchs Endothelial Corneal Dystrophy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Fuchs Endothelial Corneal Dystrophy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Fuchs Endothelial Corneal Dystrophy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Trefoil Therapeutics
• Kowa Pharmaceutical
• Santen Pharmaceutical

Key Products

• TTHX 1114
• Ripasudil hydrocholoride hydrate
• STN1010904